Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Year-end report January – December 2022
The period in summary January 1 – December 31, 2022 In the end of March the first batch of Strangvac® was released for sale in Sweden, and in the end of May we passed another milestone in the fight against strangles when Strangvac® was released for sale in...Intervacc’s Chief Scientific Officer Dr Andrew Waller presents at the FEEVA European Horse Welfare Symposium in Amsterdam
Stockholm, January 24, 2023 – Intervacc’s Chief Scientific Officer Dr Andrew Waller will talk about the prevention of equine strangles at the Federation of European Equine Veterinary Associations (FEEVA) European Horse Welfare Symposium 2023 on the 28th of...Intervacc’s Chief Scientific Officer Dr Andrew Waller presents at the Veterinary Sport Horse Congress in Amsterdam
Stockholm, January 23, 2023 – The 17th edition of the Veterinary Sport Horse Congress in Amsterdam which attracts veterinarians from all over the globe, is an opportunity for attendees to learn about the latest research and developments in equine sports...Intervacc and the Swedish University of Agricultural Sciences, SLU, extends a multi-year contract for the development of innovative animal health vaccines
Stockholm, December 19th, 2022 – Intervacc AB (publ) and the Swedish University of Agricultural Sciences, SLU, announce today that they have extended the contract for the development of animal health vaccines using recombinant proteins. The successful...Strangvac, a vaccine against equine strangles released for sales in Italy
Stockholm, December 13th, 2022 – Intervacc AB (publ) announces today that the first batch of Strangvac®, a vaccine against the highly contagious bacterial equine disease Strangles, has been released for sale in Italy. Dechra Pharmaceuticals PLC distributes the...Nyhetstjänster
